Do you want to read an article? Please log in or register.
Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial
Head and Neck Cancer
Related content
Gastrointestinal Cancer
A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse
Ann Oncol
Blay JY, Schiffler C, Bouché O, Brahmi M, Duffaud F, Toulmonde M, Landi B, Lahlou W, Pannier D, Bompas E, Bertucci F, Chaigneau L, Collard O, Pracht M, Henon C, Ray-Coquard I, Armoun K, Salas S, Spalato-Ceruso M, Adenis A, Verret B, Penel N, Moreau-Bachelard C, Italiano A, Dufresne A, Metzger S, Chabaud S, Perol D, Le Cesne A
doi: 10.1016/j.annonc.2024.08.2343
Head and Neck Cancer
Reduced-volume radiotherapy versus conventional-volume radiotherapy after induction chemotherapy in nasopharyngeal carcinoma: An open-label, noninferiority, multicenter, randomized phase 3 trial
CA Cancer J Clin
Tang LL, Chen L, Xu GQ, Zhang N, Huang CL, Li WF, Mao YP, Zhou GQ, Lei F, Chen LS, Huang SH, Chen L, Chen YP, Zhang Y, Liu X, Xu C, Zhao Y, Li JB, Liu N, Xie FY, Guo R, Sun Y, Ma J
doi: 10.3322/caac.21881
Gynecologic Cancer
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
Lancet
McCormack M, Eminowicz G, Gallardo D, Diez P, Farrelly L, Kent C, Hudson E, Panades M, Mathew T, Anand A, Persic M, Forrest J, Bhana R, Reed N, Drake A, Adusumalli M, Mukhopadhyay A, King M, Whitmarsh K, McGrane J, Colombo N, Mak C, Mandal R, Chowdhury RR, Alamilla-Garcia G, Chávez-Blanco A, Stobart H, Feeney A, Vaja S, Hacker AM, Hackshaw A, Ledermann JA, INTERLACE investigators
doi: 10.1016/S0140-6736(24)01438-7
Central Nervous System Tumors
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group
Neuro Oncol
Mazewski C, Leary SES, Kang G, Li BK, Kellie S, Hayes L, Shaw D, Ho B, Reddy A, Gossett J, Burger PC, Judkins AR, Aridgides P, Geyer JR, Gajjar A, Pollack IF, Fouladi M, Huang A
doi: 10.1093/neuonc/noaf132
Skin Cancer
Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial
Lancet Oncol
Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D
doi: 10.1016/S1470-2045(25)00139-1
COMMENTED
Gynecologic Cancer
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Lancet
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, Acevedo A, Cvek J, Randall L, Pereira de Santana Gomes AJ, Contreras Mejía F, Helpman L, Akıllı H, Lee JY, Saevets V, Zagouri F, Gilbert L, Sehouli J, Tharavichitkul E, Lindemann K, Colombo N, Chang CL, Bednarikova M, Zhu H, Oaknin A, Christiaens M, Petru E, Usami T, Liu P, Yamada K, Toker S, Keefe SM, Pignata S, Duska LR, ENGOT-cx11/GOG-3047/KEYNOTE-A18 investigators
doi: 10.1016/S0140-6736(24)01808-7
Breast Cancer
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial
JAMA Oncol
Partridge AH, Hyslop T, Rosenberg SM, Bennett AV, Drier S, Jonsson M, Shimada A, Li Y, Li Y, Lynch T, Frank E, Collyar D, Basila D, Pinto D, Weiss A, Wolf A, Norris K, Witten M, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Darai S, Carey L, Thompson A, Hwang ES, COMET Study Consortium
doi: 10.1001/jamaoncol.2024.6556
Genitourinary Cancer
Avelumab + axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase 3 JAVELIN Renal 101 trial
Ann Oncol
Choueiri TK, Penkov K, Uemura H, Campbell MT, Pal S, Kollmannsberger C, Lee JL, Venugopal B, van den Eertwegh AJM, Negrier S, Gurney H, Albiges L, Berger R, Haanen JBAG, Oyervides Juárez V, Rini BI, Larkin J, Nolè F, Schmidinger M, Atkins MB, Tomita Y, Ellers-Lenz B, Hoffman J, Sandner R, Wang J, di Pietro A, Motzer RJ
doi: 10.1016/j.annonc.2024.12.008
COMMENTED
Gynecologic Cancer
ENGOT-en11/GOG-3053/KEYNOTE-B21: A Randomised, Double-Blind, Phase 3 Study of Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer
★ 0
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
Van Gorp T, Cibula D, Lv W, Backes F, Ortaç F, Hasegawa K, Lindemann K, Savarese A, Laenen A, Kim YM, Bodnar L, Barretina-Ginesta MP, Gilbert L, Pothuri B, Chen X, Flores MB, Levy T, Colombo N, Papadimitriou C, Buchanan T, Hanker LC, Eminowicz G, Rob L, Black D, Lichfield J, Lin G, Orlowski R, Keefe S, Lortholary A, Slomovitz B, ENGOT-en11/GOG-3053/KEYNOTE-B21 investigators
doi: 10.1016/j.annonc.2024.08.2242